Tenofovir News and Research

RSS

Long-acting HIV prevention tools could help close the gap before a vaccine arrives

A review of non-vaccine HIV interventions highlights the strong preventive effects of long-acting PrEP, sustained ART, U=U, vertical transmission programs, and voluntary medical male circumcision. Gene editing and multispecific antibodies may expand future options, but safety, cost, access, adherence, and implementation barriers remain.

5 Aug 2026

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

A systematic review identified 41 human studies evaluating interventions targeting next-generation DNA methylation-based aging clocks. Pharmaceutical, lifestyle, supplement, clinical, and psychosocial interventions shifted some clock outputs, but these biomarkers remain investigational rather than proven clinical surrogates.

16 Jun 2026

Combination therapy improves response rates for chronic hepatitis B patients

The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This study aimed to investigate the efficacy and predictive factors of a pegylated interferon (Peg-IFN)-based treatment strategy in IT patients with chronic HBV infection.

22 May 2026

Long-term study supports tenofovir alafenamide for chronic hepatitis B

Tenofovir alafenamide (TAF) has demonstrated comparable efficacy to tenofovir disoproxil fumarate (TDF), with improved renal and bone safety, in Chinese participants with chronic hepatitis B enrolled in two Phase 3 trials.

24 Apr 2026

To knock down health-system hurdles between you and HIV prevention, try these 6 things

A couple of years ago, Matthew Hurley got the kind of text people fear.

5 Jan 2026

Tenofovir amibufenamide shows efficacy in chronic hepatitis B patients with normal ALT

Chronic hepatitis B virus (HBV)-infected patients may exhibit liver fibrosis and other pathological changes despite normal alanine aminotransferase (ALT).

19 Aug 2025

Australian study uncovers first potential prophylactic treatment against HTLV-1

Around 10 million people globally live with the life-threatening virus HTLV-1. Yet it remains a poorly understood disease that currently has no preventative treatments and no cure.

21 Jul 2025

Twice-yearly injection could transform HIV prevention efforts

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a stalwart for HIV prevention-but only if people take it consistently and can routinely access a pharmacy.

3 Jul 2025

Vaginal microbiome fights back against stubborn BV infections

Vaginal microbiome-drug interactions affect antibiotic treatment for bacterial vaginosis, emphasizing the need for personalized approaches to enhance efficacy.

3 Jul 2025

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

Hepatitis B is a liver infection cause by the hepatitis B virus (HBV), and long-term hepatitis B infections that last longer than six months are considered "chronic".

24 Mar 2025

Global study sheds light on differences in medicine taste sensitivity

Many medicines taste so bitter that some people avoid taking them. To help with the bad taste, flavors and sweeteners are added to modify the taste and make it more acceptable.

4 Mar 2025

Study evaluates effectiveness and safety of TMF for chronic hepatitis B

Chronic hepatitis B (CHB) remains a significant global health challenge, and effective antiviral therapies are essential for long-term management.

17 Jan 2025

Tenofovir amibufenamide does not alter lipid levels in patients with chronic hepatitis B

The effect of tenofovir amibufenamide (TMF) on blood lipid profiles in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to explore whether TMF affects blood lipids during 48 weeks in patients with CHB.

26 Oct 2024

Integrated HIV prevention strategy increases PrEP adherence among transgender women

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and feasibility of an integrated multicomponent strategy to enhance daily oral HIV pre-exposure prophylaxis (PrEP) uptake and adherence among transgender women in a randomized immediate versus deferred design.

12 Oct 2024

Abacavir linked to increased cardiovascular risk in HIV patients, study finds

CJ Fichtenbaum et al. Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. International AIDS Conference. Friday, July 26, 2024

23 Jul 2024

Long-acting injectable CAB-LA safe for HIV PrEP during pregnancy, study finds

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study among cisgender women.

23 Jul 2024

Navigating adjuvant therapy options in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths.

16 Jul 2024

Global increase in deaths from viral hepatitis revealed in WHO report

According to the World Health Organization (WHO) 2024 Global Hepatitis Report, the number of lives lost due to viral hepatitis is increasing.

10 Apr 2024

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started using one of them in their second trimester of pregnancy, according to findings presented today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

Research validates concurrent use of HIV medications and gender-affirming hormone therapy

New research definitively shows that HIV antiretrovirals can be taken together with gender-affirming hormone therapy without changing how well either drug works.

4 Mar 2024